Amyrt’s AP103 Receives the US FDA’s Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)

Shots:

• The US FDA has granted orphan drug designation for AP103 for the treatment of DEB
• Amyrt licensed a pre-clinical gene – therapy platform technology to treat patients with DEB, a subset of EB also applicable for genetic disorders in Mar 2018
• AP103 is based on a novel polymer-based topical delivery platform and offers potential advantages in the gene therapy field also used in other genetic skin conditions

Click here ­to­ read full press release/ article | Ref: GlobeNewswire  | Image: Twitter